Clinical Trial of Repeated Intraperitoneal Administration of GAIA-102 in Patients With Advanced Gastrointestinal Cancer (Gastric Cancer / Pancreatic Cancer) of Microsatellite Stable (MSS) With Malignant Ascites (Phase I / II Investigator-initiated Clinical Trial) (GAIA-102-PD Clinical Trial)
Latest Information Update: 21 Nov 2025
At a glance
- Drugs GAIA 102 (Primary) ; Pembrolizumab (Primary)
- Indications Gastric cancer; Malignant ascites; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms GAIA-102-PD
Most Recent Events
- 18 Nov 2025 Planned number of patients changed from 96 to 130.
- 18 Nov 2025 Planned End Date changed from 8 Jun 2027 to 31 Mar 2029.
- 18 Nov 2025 Planned primary completion date changed from 31 Dec 2026 to 31 Dec 2028.